Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

Trial ID or NCT#

NCT04994249

Status

recruiting iconRECRUITING

Purpose

To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.

Official Title

Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - 1) Inclusion criteria: Adults (18-80 years; ~64% female expected based on clinic distribution) with chronic MSP as categorized by the World Health Organization (WHO).
Exclusion Criteria:
  1. - 1) Chronic musculoskeletal pain (MSP) explained by inflammatory disease (e.g., rheumatoid arthritis, lupus) or CP with a primary diagnosis other than chronic MSP (e.g., neuropathic pain), (2) significant cognitive impairment, (3) MRI contraindication, (4) medical or psychiatric problems interfering with the study, (5) current medicolegal factors (e.g., open disability claim), (6) plans for surgery during the study, (7) pregnancy and (8) Children under the age of 18 will not be included in the study.

Investigator(s)

Sean Mackey, M.D., Ph.D.
Sean Mackey, M.D., Ph.D.
Pain management specialist, Pain management specialist, Anesthesiologist
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology

Contact us to find out if this trial is right for you.

Contact

Anne Cunniffe Marcy, MSBH
650-721-6931